WallStreetZenWallStreetZen

NASDAQ: KRON
Kronos Bio Inc Stock Forecast, Predictions & Price Target

Analyst price target for KRON

Based on 2 analysts offering 12 month price targets for Kronos Bio Inc.
Min Forecast
$2.50+142.72%
Avg Forecast
$4.25+312.62%
Max Forecast
$6.00+482.52%

Should I buy or sell KRON stock?

Based on 2 analysts offering ratings for Kronos Bio Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KRON stock forecasts and price targets.

KRON stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-12-19
lockedlocked$00.00+00.00%2023-12-19

1 of 1

Forecast return on equity

Is KRON forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.66%

Forecast return on assets

Is KRON forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

KRON revenue forecast

What is KRON's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$6.5M+3.37%
Avg 2 year Forecast
$5.0M-20.48%
KRON's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

KRON revenue growth forecast

How is KRON forecast to perform vs Biotechnology companies and vs the US market?
Company
-17.74%
Industry
37.96%
Market
10.23%
KRON's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
KRON's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

KRON vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KRON$1.03$4.25+312.62%Strong Buy
LTRN$5.77N/AN/A
CELU$3.21N/AN/A
TSBX$2.71N/AN/A
HCWB$1.66N/AN/A

Kronos Bio Stock Forecast FAQ

Is Kronos Bio Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: KRON) stock is to Strong Buy KRON stock.

Out of 2 analysts, 1 (50%) are recommending KRON as a Strong Buy, 1 (50%) are recommending KRON as a Buy, 0 (0%) are recommending KRON as a Hold, 0 (0%) are recommending KRON as a Sell, and 0 (0%) are recommending KRON as a Strong Sell.

If you're new to stock investing, here's how to buy Kronos Bio stock.

What is KRON's revenue growth forecast for 2024-2025?

(NASDAQ: KRON) Kronos Bio's forecast annual revenue growth rate of -17.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Kronos Bio's revenue in 2024 is $6,288,000.On average, 2 Wall Street analysts forecast KRON's revenue for 2024 to be $390,617,585, with the lowest KRON revenue forecast at $240,380,052, and the highest KRON revenue forecast at $540,855,117.

In 2025, KRON is forecast to generate $300,475,065 in revenue, with the lowest revenue forecast at $300,475,065 and the highest revenue forecast at $300,475,065.

What is KRON's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: KRON) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is KRON's Price Target?

According to 2 Wall Street analysts that have issued a 1 year KRON price target, the average KRON price target is $4.25, with the highest KRON stock price forecast at $6.00 and the lowest KRON stock price forecast at $2.50.

On average, Wall Street analysts predict that Kronos Bio's share price could reach $4.25 by Dec 19, 2024. The average Kronos Bio stock price prediction forecasts a potential upside of 312.62% from the current KRON share price of $1.03.

What is KRON's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: KRON) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.